Lokivetmab
Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31 monoclonal antibody. Lokivetmab inhibits IL-31-mediated activation of pruritogenic signals in peripheral sensory neurons and reduces TH2-weighted inflammation. Lokivetmab demonstrates long-term efficacy in controlling pruritus and improving skin lesions in dogs with canine atopic dermatitis (CAD) . Lokivetmab can be used for the research of atopic dermatitis (AD) in dogs[1].
Product Specifications
CAS Number
1533403-95-0
Product Name Alternative
Anti-Canine IL31 Recombinant Antibody; CAN34D3-65; PF-06443537
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lokivetmab.html
Purity
99.0
Solubility
H2O
Smiles
[Lokivetmab]
Molecular Weight
(147.51 kDa)
References & Citations
[1]Gober M, et al. Long term use of lokivetmab (Cytopoint®) in atopic dogs. BMC Vet Res. 2025 Mar 26;21 (1) :203.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Colloidal Gold Conjugated Goat Affinity Purified Antibody to Bovine IgG, 5nm
